Complete remission with Immunotherapy in second-Line in metastatic lung cancer without targetable oncogenic addiction: About a case and revue of the literature
1 Mohamed VI center for the treatment of cancer, Casablanca.
2 Department of Radiotherapy, Hassan II university hospital, Fez.
3 internal medecine department, Ibn Rochd university hospital, Casablanca.
Case Study
World Journal of Advanced Research and Reviews, 2023, 17(03), 598–601
Article DOI: 10.30574/wjarr.2023.17.3.0370
Publication history:
Received on 25 January 2023; revised on 11 March 2023; accepted on 14 March 2023
Abstract:
Lung cancer is a public health problem in the world, en 2020: 2nd most common cancer after breast cancer. Smoking is the main risk factor constituting an essential axis of prevention. Non-small cell lung cancer is the most common histological component representing approximately 85%, currently 75% of patients have unfortunately become at advanced stages, the prognosis remains poor: incidence and expectation are close, but metastatic NSCLC has experienced a total renewal of the therapeutic arsenal. It is a model of precision medicine and also in particular a model for immunotherapy. We are recently faced with an expanded therapeutic arsenal posing a problem of choice. with a durable complete response with Atezolizumab.
Keywords:
Metastatic Lung cancer; Chemotherapy PDL-1; Atezolizumab; Case
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0